PMID- 21297371
OWN - NLM
STAT- MEDLINE
DCOM- 20110517
LR  - 20211203
IS  - 0031-6903 (Print)
IS  - 0031-6903 (Linking)
VI  - 131
IP  - 2
DP  - 2011 Feb
TI  - [Exploratory study on biomarkers associated with severe cutaneous adverse 
      reactions].
PG  - 255-61
AB  - Most of adverse drug reactions (ADRs) occur as an extension of pharmacological 
      effects. They occur dependently on their blood concentrations and can be 
      potentially reduced by controlling their dose. On the other hand, ADRs 
      categorized as Type B usually occur irrelevantly to their pharmacological effects 
      at different organs from their target, and are often life-threatening and 
      unpredictable. The incidences of Type B ADRs are very low. Severe cutaneous 
      adverse reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal 
      necrolysis (TEN) are delayed allergic reactions in which T-cells are involved and 
      categorized as Type B ADRs. Recent progress of pharmacogenomic studies has 
      revealed that particular types of human leukocyte antigen (HLA) class I antigens 
      have strong associations with severe cutaneous adverse reactions and that the 
      associations are specific to causative drugs, phenotypes of adverse reactions and 
      ethnic groups. We established a research group in 2006 with professionals of 
      pharmacogenomics, dermatologists, ophthalmologists and psychiatrists to explore 
      genetic biomarkers associated with Japanese SJS/TEN patients. To date, we have 
      collected more than 100 Japanese SJS/TEN patients through participating 
      institutes and a case-collecting system covering all over Japan constructed by 
      us. No carriers of HLA-B*1502 which was reported to have extremely strong 
      association with carbamazepine-induced SJS/TEN in Han Chinese and south Asians, 
      although a moderate association between allopurinol-induced SJS/TEN and 
      HLA-B*5801 detected in Han Chinese was observed.
FAU - Kaniwa, Nahoko
AU  - Kaniwa N
AD  - Division of Medicinal Safety Science, National Institute of Health Sciences, 
      Tokyo. nkaniwa@nihs.go.jp
LA  - jpn
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - 0 (HLA-B Antigens)
RN  - 33CM23913M (Carbamazepine)
RN  - 63CZ7GJN5I (Allopurinol)
SB  - IM
MH  - Allopurinol/adverse effects
MH  - Carbamazepine/adverse effects
MH  - HLA-B Antigens/*genetics
MH  - Humans
MH  - Pharmacogenetics
MH  - Racial Groups
MH  - Stevens-Johnson Syndrome/etiology/*genetics
MH  - T-Lymphocytes/immunology
EDAT- 2011/02/08 06:00
MHDA- 2011/05/18 06:00
CRDT- 2011/02/08 06:00
PHST- 2011/02/08 06:00 [entrez]
PHST- 2011/02/08 06:00 [pubmed]
PHST- 2011/05/18 06:00 [medline]
AID - JST.JSTAGE/yakushi/131.255 [pii]
AID - 10.1248/yakushi.131.255 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2011 Feb;131(2):255-61. doi: 10.1248/yakushi.131.255.